iBio (IBIO) Corporate presentation summary

Strategic rationale

• Incretin therapies have transformed obesity care; next-generation approaches target weight-loss durability, lean-mass preservation, tolerability and convenience.

• A cited study found 0.32 kg of lean tissue lost per 1 kg of weight loss and only 0.08 kg regained per 1 kg of weight regained; a weight loss/regain group had 39% higher frailty-fracture risk vs control.

• Portfolio strategy targets multiple mechanisms beyond incretins, aiming for fat-specific loss, muscle preservation, fewer adverse effects and less frequent dosing.

Pipeline and catalysts

• Pipeline includes IBIO-610, IBIO-800, IBIO-600, an amylin antibody and Target 4; the presentation cites four high-novelty programs plus one partnered program.

• IBIO-610 IND-equivalent filing expected 4Q 2026 and first patient dosing expected 1H 2027; IBIO-800 filing expected 1H 2027.

• IBIO-600 interim Phase 1 data anticipated 1Q 2027; discovery candidates for amylin and Target 4 targeted for 2H 2027.

IBIO-610 Activin E antibody

• Long-acting antibody targets liver-derived Activin E, a genetically validated hepatokine linked to adipose metabolism; intended for standalone, combination and maintenance use.

• In obese NHPs, terminal half-life was 33.2 days and active Activin E suppression reached at least 97% at week 8 after a 10 mg/kg IV dose; n=4–6 per group.

• After doses at weeks 0 and 8, obese NHPs showed week-16 changes of -6.7% visceral fat, -5.2% total fat mass and +0.9% total lean mass; n=4–6 per group.

• With semaglutide in obese NHPs, lean tissue was 6% of mass lost with IBIO-610 combination vs 22% with semaglutide alone; semaglutide was titrated to 30 μg/kg BIW.